All Vaccinology articles – Page 2
-
NewsNanodisc platform improves vaccine design for Ebola, HIV and more
Scientists have created a platform that allows viral surface proteins to be studied in a form that more closely resembles how they appear naturally, utilizing nanodisc technology where these proteins are embedded into particles made of lipid molecules, preserving them in a membrane-like structure.
-
NewsTrial assesses safety and effectiveness of two new TB vaccines
Two new vaccines to prevent tuberculosis (TB) are safe for use in adults and children, but they do not offer protection against all forms of TB, finds a large trial from India.
-
NewsImmunogenicity and safety of an Escherichia coli-produced 9-valent HPV vaccine in adolescents compared with young women
Based on new findings, the National Medical Products Administration of China has approved a two-dose immunization schedule for the domestically produced 9-valent HPV vaccine in girls aged 9 to 17 years.
-
NewsA smarter way to build vaccines: scientists harness AI to target emerging alphaviruses
Scientists have developed a new computational pipeline that could dramatically accelerate the development of vaccines against a group of mosquito-borne viruses known as alphavirus.
-
NewsPhase I study for human monoclonal antibody for Lyme disease demonstrates safety, tolerability, pharmacokinetics
A Phase I clinical trial of a human monoclonal antibody discovered and developed for the prevention of Lyme disease in the U.S. was well tolerated and showed lasting serum concentrations in participants, according to data.
-
NewsRisk of Alzheimer’s dementia significantly reduced after high-dose influenza vaccination compared to the standard dose
The risk of Alzheimer’s disease significantly decreases in older adults who receive a higher dose of the influenza vaccine compared to the standard dose, according to new research.
-
NewsInequalities in childhood pneumococcal vaccine uptake persist in England despite schedule change
Vaccine uptake data has been examined to assess the impact of moving from a ‘2+1’ to a ‘1+1’ Pneumococcal Conjugate Vaccine (PCV) dose schedule on vaccine coverage and health inequalities among infants in England.
-
NewsScientists develop therapeutic, nasally delivered DNA vaccine for tuberculosis
Research shows the vaccine — in combination with drug therapy — accelerated a relapse-free TB cure in mice, improved activity of a drug-resistant TB regimen and stimulated immune responses in nonhuman primates.
-
NewsNew vaccine strategy could help extend immunity against evolving viruses
Researchers have identified a possible way to make longer lasting vaccines for respiratory viruses like influenza and the coronavirus that causes COVID-19.
-
FeaturesCan we make a vaccine against the next Disease X in 100 days?
The COVID-19 pandemic was one of the deadliest events in modern history. Estimated to have killed over 25 million people worldwide and caused trillions of dollars in economic damage, the devastation caused by this virus was both astronomical and unforgettable.
-
NewsWhy is vaccination for target populations plummeting in the UK? Share your insights!
As a group of leading UK health experts launches a new Commission on Access to Vaccines to understand why access levels are falling across the UK, Applied Microbiology International is calling on members to share their insights on childhood vaccinations.
-
NewsTracking bacteria’s protective armor could help find targeted vaccine targets
The first large-scale genetic study of E. coli’s protective armour has identified the five capsule types that are responsible for 70 per cent of all multidrug-resistant bloodstream infections in Europe.
-
NewsHPV vaccination uptake in adults shaped by knowledge and medical advice
A nationwide survey of HPV uptake in Switzerland found just over 27% of the approximately 3,850 adults aged 18 to 45 surveyed had received at least one dose of the vaccine. While nearly 59% of those aged 18 to 26 are vaccinated, the rate drops to around 16% among those aged 27 to 45.
-
NewsHealth experts from a new Commission call for a step change in vaccine access as coverage falls and potentially preventable outbreaks return
A group of leading UK health experts have today announced that they will be launching the Commission on Access to Vaccines to understand why access levels are falling across the UK and to recommend practical measures to reform vaccine delivery across the health system.
-
NewsWHO recommends new diagnostic tools to help end TB
On World TB Day, WHO is urging countries to accelerate action to end tuberculosis (TB) and expand access to lifesaving services by using new innovations such as diagnostic tests that can be used near the point-of-care and tongue swabs that can help detect the disease faster.
-
NewsHKU innovations achieve recognition at the 51st International Exhibition of Inventions at Geneva
The University of Hong Kong (HKU) secured 46 awards at the 51st International Exhibition of Inventions of Geneva, including recognition for a project aiming to gain immunity against the three major respiratory viruses through home-based toothbrushing.
-
NewsFrequent infections in nursery help toddlers build up immune systems
Young children who attend nursery get sick more often than those who don’t, but they will go on to have fewer illnesses during early school years, finds a new review of evidence by a group of parent-scientists.
-
NewsTargeting two flu proteins sharply reduces airborne spread
A study in ferrets — which have remarkably similar respiratory systems to humans — suggests that immunity to two proteins in the H1N1 influenza virus sharply reduces transmission.
-
NewsHow one flu virus can hamper the immune response to another
Prior exposure to one strain of influenza virus may weaken children’s ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study.
-
NewsDengue vaccine remains 80.5% effective against severe cases after five years
The tetravalent dengue vaccine was 80.5% effective against severe dengue cases with warning signs over a five-year period. Overall, the vaccine was 65% effective in preventing symptomatic dengue (caused by any serotype) during the five years of monitoring.